Cargando…

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

BACKGROUND & AIMS: Non‐alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non‐alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the preval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calleja, José L., Rivera‐Esteban, Jesús, Aller, Rocío, Hernández‐Conde, Marta, Abad, Javier, Pericàs, Juan M., Benito, Hugo G., Serra, Miguel A., Escudero, Amparo, Ampuero, Javier, Lucena, Ana, Sánchez, Yolanda, Arias‐Loste, María T., Iruzubieta, Paula, Romero‐Gómez, Manuel, Augustin, Salvador, Crespo, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Metabolic & Toxic Liver Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541569/ https://www.ncbi.nlm.nih.gov/pubmed/35643936 http://dx.doi.org/10.1111/liv.15323

Ejemplares similares

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

Serum aromatic and branched‐chain amino acids associated with NASH demonstrate divergent associations with serum lipids
por: de Mello, Vanessa D., et al.
Publicado: (2020)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
por: Mendoza, Yuly P., et al.
Publicado: (2021)

High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort
por: Llop, Elba, et al.
Publicado: (2021)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study)
por: Lavín-Alconero, Lucía, et al.
Publicado: (2021)

NAFLD is related to Post‐prandial Triglyceride‐enrichment of HDL Particles in Association with Endothelial and HDL Dysfunction
por: Verwer, Bart J., et al.
Publicado: (2020)

Impact of osteopontin on the development of non‐alcoholic liver disease and related hepatocellular carcinoma
por: Nardo, Alexander D., et al.
Publicado: (2020)

Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease
por: Sangineto, Moris, et al.
Publicado: (2020)

The endothelial function biomarker soluble E‐selectin is associated with nonalcoholic fatty liver disease
por: Simons, Nynke, et al.
Publicado: (2020)

Absence of Bsep/Abcb11 attenuates MCD diet‐induced hepatic steatosis but aggravates inflammation in mice
por: Fuchs, Claudia D., et al.
Publicado: (2020)

Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
por: Yen, Fu‐Shun, et al.
Publicado: (2020)

Oxidative stress is associated with suspected non‐alcoholic fatty liver disease and all‐cause mortality in the general population
por: Damba, Turtushikh, et al.
Publicado: (2020)

Mesenchymal iron deposition is associated with adverse long‐term outcome in non‐alcoholic fatty liver disease
por: Eder, Sebastian K., et al.
Publicado: (2020)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Interaction between CHOP and FoxO6 promotes hepatic lipid accumulation
por: Kim, Dae Hyun, et al.
Publicado: (2020)

Diagnostic accuracy of fibrosis tests in children with non‐alcoholic fatty liver disease: A systematic review
por: Draijer, Laura G., et al.
Publicado: (2021)

Circulating trimethylamine‐N‐oxide is associated with all‐cause mortality in subjects with nonalcoholic fatty liver disease
por: Flores‐Guerrero, Jose L., et al.
Publicado: (2021)

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
por: Colosimo, Santo, et al.
Publicado: (2021)

Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
por: George, Elena S., et al.
Publicado: (2022)

Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment
por: Lazure, Patrice, et al.
Publicado: (2022)

Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008‐2019
por: Sugiyama, Aya, et al.
Publicado: (2021)

Risk of hepatic and extrahepatic cancer in NAFLD: A population‐based cohort study
por: Björkström, Karl, et al.
Publicado: (2022)

Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
por: Balkhed, Wile, et al.
Publicado: (2022)

Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
por: Villeret, François, et al.
Publicado: (2022)

Inhibition of polyploidization in Pten‐deficient livers reduces steatosis
por: Moreno, Eva, et al.
Publicado: (2022)

Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
por: Braude, Michael, et al.
Publicado: (2022)

Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience
por: Barbas, Andrew S., et al.
Publicado: (2017)

The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?
por: Iruzubieta, Paula, et al.
Publicado: (2015)

Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes
por: Carrieri, Patrizia, et al.
Publicado: (2022)

Stratification of patients in NASH clinical trials: A pitfall for trial success
por: Ampuero, Javier, et al.
Publicado: (2020)

What we need to know when performing and interpreting US elastography
por: Park, So Hyun, et al.
Publicado: (2016)

LOXL2—A New Target in Antifibrogenic Therapy?
por: Puente, Angela, et al.
Publicado: (2019)

DNA topoisomerase VIII: a novel subfamily of type IIB topoisomerases encoded by free or integrated plasmids in Archaea and Bacteria
por: Gadelle, Danièle, et al.
Publicado: (2014)

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
por: Bagri, Puneet Kumar, et al.
Publicado: (2014)

Radiotherapy-enhanced ototoxicity in elderly
por: Malgonde, Monika S., et al.
Publicado: (2014)

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities
por: Xiao, Canhua, et al.
Publicado: (2018)

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy
por: Amin, Neha P., et al.
Publicado: (2018)

Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data
por: Holyoake, Daniel L.P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a5b704re5pkesviqkicnlcp070